MetaCap

Enliven Therapeutics (ELVN) vs Xenon Pharmaceuticals (XENE)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Enliven Therapeutics (ELVN) has outperformed Xenon Pharmaceuticals (XENE) over the past year, gaining 113.9% versus a loss of 10.0%. Over five years, ELVN leads with a +254.6% price change compared with +35.0% for XENE. Xenon Pharmaceuticals is the larger company by market cap ($3.64 billion vs $3.42 billion), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ELVN+113.93%XENE-10.01%
+192%+75%-41%
Nov 21, 20251 yearNov 20, 2026
ELVN+252.50%XENE+27.77%
+379%+145%-90%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ELVN versus XENE key metrics
MetricELVNXENE
Share price$46.53$37.04
Market cap$3.42B$3.64B
1-day change+0.26%-1.38%
YTD return+202.14%-17.36%
1-year return+113.93%-10.01%
5-year return+254.65%+34.99%
EPS (TTM)$-1.69$-4.69
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$7.50M
Net income (latest FY)$-103.69M$-345.91M
Operating margin—-4974.27%
Net margin—-4612.13%
52-week high$62.32$72.66
52-week low$14.79$33.38
Distance from 52-week high-25.34%-49.02%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+59.75%+93.55%
Average volume1.36M1.69M
Shares outstanding73.60M98.28M
Employees65358
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ELVN has outperformed XENE by 123.9 percentage points over the past year.

About Enliven Therapeutics

ELVN stock →

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 mutant tumors.

Health Care · Biotechnology: Pharmaceutical Preparations · 65 employees

About Xenon Pharmaceuticals

XENE stock →

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression.

Health Care · Biotechnology: Pharmaceutical Preparations · 358 employees

ELVN vs XENE FAQ

Which is bigger, Enliven Therapeutics or Xenon Pharmaceuticals?

Xenon Pharmaceuticals (XENE) is larger, with a market capitalization of $3.64B compared with $3.42B for Enliven Therapeutics (ELVN).

Which stock has performed better over the past year, ELVN or XENE?

ELVN returned +113.93% over the past 12 months, compared with -10.01% for XENE (price return, excluding dividends). Past performance does not predict future results.

Are Enliven Therapeutics and Xenon Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons